22 completed, 6 unknown, 5 terminated, 4 active not recruiting. 10 Not applicable, 10 Phase 2, 6 Phase 3, 4 Phase 1, 2 Early Phase 1.
Follow AMD: new trials by email Literature Review of AMD trials Research Report on AMD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration Transcutaneous Electrical Stimulation, Sham Transcutaneous Electrical Stimulation - Dry Age-Related Macular Degeneration, AMD | Not applicable | Not yet recruiting | Nu Eyne Co., Ltd. | 40 | 2026-07-09 | 2026-07-13 |
| A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD Sanhuang Jingshiming/Pills placebo - AMD | Phase 3 | Not yet recruiting | Tasly Pharmaceutical Group Co., Ltd | 450 | 2026-04-30 | 2026-04-08 |
| Retinal Clinical Assessment With AI-derived Quantitative Information AI-derived retinal quantitative information-assisted reporting - no Obvious Abnormalities, Diabetic Retinopathy (DR) | Not yet recruiting | Beijing Tongren Hospital | 29 | 2026-04-15 | 2026-04-29 | |
| A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases Chronic Disease Intervention CDI - Glaucoma, AMD | Active not recruiting | Interstat LLC | 300 | 2024-10-10 | 2025-10-15 | |
| Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SINE) sinusitis screening consultation - AMD | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 200 | 2023-01-20 | 2025-12-10 | |
| Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration SING IMT(TM) System, model NG SI IMT 3X - AMD, Age-Related Macular Degeneration | Not applicable | Active not recruiting | VisionCare, Inc. | 68 | 2022-09-13 | 2026-09-29 |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration laser flare photometry before intravitreal injection - AMD | Not applicable | Completed | The Filatov Institute of Eye Diseases and Tissue Therapy | 30 | 2021-03-25 | 2026-01-29 |
| Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression N/A Observational study - Age Related Macular Degeneration, Geographic Atrophy | Recruiting | Center for Eye Research Australia | 2500 | 2021-02-02 | 2024-02-09 | |
| Image Biomarkers for Progression of AMD AMD | Withdrawn | Doheny Image Reading Center | 2021-01-01 | 2020-09-28 | ||
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
| Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration. Postbotics and Vitamins, Vitamins - AMD, Soft Drusen | Not applicable | Unknown | Institut de la Macula y la Retina | 48 | 2020-12-02 | 2021-09-24 |
| Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD Visucomplex Plus - AMD | Unknown | VISUfarma SpA | 160 | 2019-12-11 | 2020-04-27 | |
| Retinal Imaging Using NOTAL-OCT V3.0 NOTAL-OCT V3.0 - AMD, DR | Not applicable | Completed | Notal Vision Ltd. | 58 | 2019-12-02 | 2023-06-15 |
| Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners OCT, Visual Acuity - AMD | Not applicable | Unknown | Moorfields Eye Hospital NHS Foundation Trust | 742 | 2019-09-30 | 2021-09-17 |
| Phase 2/3 Study of ALK-001 in Geographic Atrophy ALK-001 oral capsule, Placebo oral capsule - Geographic Atrophy, Age Related Macular Degeneration | Phase 2 / Phase 3 | Completed | Alkeus Pharmaceuticals, Inc. | 200 | 2019-05-07 | 2025-11-03 |
| Dual Wavelength OCT Combined Coaxial Optical Coherence Tomography - AMD, Diabetic Retinopathy | Completed | Moorfields Eye Hospital NHS Foundation Trust | 60 | 2019-02-15 | 2022-04-12 | |
| Retinal Imaging Using NOTAL-OCT V2.5 NOTAL OCT V2.5 - AMD | Completed | Notal Vision Ltd. | 87 | 2018-07-22 | 2020-11-13 | |
| TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects TAB014 - AMD | Phase 1 | Unknown | Lee's Pharmaceutical Limited | 24 | 2018-06-15 | 2018-09-26 |
| Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On AMD, Cancer | Completed | National Eye Institute (NEI) | 709 | 2018-05-23 | 2019-03-25 |
Showing 20 of 47. Sign in to see all of them.
Macular Degeneration (20) · Geographic Atrophy (5) · Retinal Degeneration (5) · Retinal Diseases (5) · Choroidal Neovascularization (4) · Eye Diseases (4) · Diabetic Retinopathy (3) · Wet Macular Degeneration (3) · Glaucoma (2) · Retinitis Pigmentosa (2) · Alzheimer Disease (1) · Cataract (1) · Epiretinal Membrane (1) · Late-Onset Retinal Degeneration (1) · Macular Degeneration, Age-Related, 10 (1)
Eye Diseases (23) · Retinal Diseases (20) · Retinal Degeneration (18) · Eye Diseases, Hereditary (6) · Choroid Diseases (4) · Metaplasia (4) · Neovascularization, Pathologic (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Uveal Diseases (4) · Cardiovascular Diseases (3) · Diabetes Complications (3) · Diabetes Mellitus (3) · Diabetic Angiopathies (3) · Endocrine System Diseases (3)
Ranibizumab (5) · anecortave acetate (4) · aflibercept (3) · Bevacizumab (2) · Drug Delivery Systems (1) · Electric Stimulation (1) · Resveratrol (1) · Tomography, Optical Coherence (1) · Transcutaneous Electric Nerve Stimulation (1) · Visual Acuity (1) · Vitamins (1) · efalizumab (1) · fosbretabulin (1) · retinol palmitate (1)
National Eye Institute (NEI) (7) · Alcon Research (4) · AbbVie (2) · Moorfields Eye Hospital NHS Foundation Trust (2) · Notal Vision Ltd. (2) · Oraya Therapeutics, Inc. (2) · VisionCare, Inc. (2) · Alkeus Pharmaceuticals, Inc. (1) · Beijing Tongren Hospital (1) · Center for Eye Research Australia (1) · Centre Hospitalier Intercommunal Creteil (1) · Centre Hospitalier Universitaire Dijon (1) · Changhua Christian Hospital (1) · Doheny Image Reading Center (1) · Fondation Ophtalmologique Adolphe de Rothschild (1)
United States (20) · France (6) · United Kingdom (6) · Italy (5) · Germany (4) · China (3) · Spain (3) · Austria (2) · Canada (2) · Israel (2) · Australia (1) · Belgium (1) · Czechia (1) · Hungary (1) · India (1)
Emily Y Chew, M.D. (4) · Terry Wiernas, PhD (2) · Andrii MD Korol, PhD (1) · Catherine A Cukras, M.D. (1) · Daniel E Salazar, PhD (1) · David G Birch, PhD (1) · Denis O'Shaughnessy, Ph.D. (1) · Dohyoung Kim (1) · Fnu Ruchi, Ph.D. (1) · Jason S Slakter, MD (1) · Jordi Mones, MD, PhD (1) · Konstantinos Balaskas (1) · Oliver D Schein, MD (1)
PMID 37702300, PMID 16508423, PMID 16508424, PMID 17031287, PMID 17698196, PMID 18843500, PMID 19680279, PMID 20574018, PMID 20926818, PMID 21623685, PMID 23316779, PMID 23638418, PMID 25142373, PMID 26545317, PMID 29110945, PMID 31942430, PMID 32844399, PMID 33980536, PMID 37315571, PMID 41638748, PMID 41759060, PMID 42242606, PMID 42295759